



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE TEAMS MEETING 14<sup>th</sup> June 2023

#### PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL ICB
Dr S Ramtoola (SR)	Consultant Physician, ELHT (Chairperson)
Mr J Vaughan (JV)	Senior Medicines Commissioning Pharmacist NHS EL/BwD ICB
Ms Ana Batista (AB)	Medicines Information Pharmacist ELHT
Mr U Akram (UA)	Deputy Lead Pharmacist, LS CFT
Ms L Prince (LP)	Senior Medicines Management Technician, EL ICB
Dr S Jackson (SJ)	GPwSI in therapeutics
Mrs H Robinson (HR)	Divisional Lead Pharmacist – MEC

#### IN ATTENDANCE:

Miss Toluwani Daramola	Specialist Pharmacist
Mr Charles Grimley	Consultant gastroenterologist
Mr Kit Patel	Specialist Pharmacy

#### 2023/68: APOLOGIES:

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr F Shah (FS)	GP/Consultant MFOP & Diabetes
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Mr C Woods (CW)	Head of Contracting and Costing, Finance

#### 2023/69: DECLARATION OF INTEREST

None declared.

#### 2023/70: MINUTES OF MARCH TEAMS MEETING:

Accepted as accurate record.

#### 2023/71: MATTERS ARISING:

**2021/101b/ 2023/09:** ELMMB Membership – to remain on action matrix as a standing item for feedback.

**ELMMB meetings:** LR updated the group. ELMMB website will 'close' in July and the site will be archived and not be updated. Any new updates to be included on LSC website. A link included on ELMMB referring visitors to LSCMMG. There is ongoing work to agree a LSC wide formulary.



The terms of reference and membership will be reviewed and brought to the next meeting. The role, functions, and further membership of the group to be looked into with a view to include other stakeholders.

**ACTION:** ELMMB terms of reference to be reviewed by LR, VG, HR and AB and brought to July meeting. AB to arrange meeting.

**2023/26: GLT2i dosing considerations according to eGFR when treating T2D, HF or CKD – Draft version.** The document has been reviewed following previous comments by Andrew Foster. However further comments suggested:

- Remove the drug costs as these may change over time.
- Table needs to specify when to use the drugs.

SJ to forward comments to JV who will amend the documents in liaison with AF.

Final document to be brought back to next meeting. It was suggested it could then go to LSCMMG for adoption.

**ACTION:** updated/final document to be brought back to next meeting

**2023/57b: Dailiport 3 mg prolonged-release hard capsules (tacrolimus).** David Jones at Preston has been emailed regarding their position; no definitive position provided yet. Flagged with LSCMMG and the item has been prioritised for review in September. Suggested at LSCMMG that patients should not be switched from Advagraf® until the review has taken place. However, new patients may be initiated on Dailiport®.

**Resolved:** Agreed that we will keep using Advagraf® locally until LSCMMG review complete.

#### **2023/72: New Product Request**

- Short Chain Fatty Acid Enema Solution 50ml: requested by Dr C Grimley** (Consultant gastroenterologist) for treatment of diversion colitis in patients who can't undergo surgical anastomosis. Its use will be to support symptom control whilst patient is awaiting proctectomy. **RED traffic Light**
- Bezafibrate 200mg and 400mg MR tablet:** requested by Dr I Gkikas (Consultant Hepatologist) as a first line option in pruritis secondary to primary sclerosing cholangitis. Approved as an unlicensed indication; to include caution that it should not be prescribed alongside another statin. Approved for use. **AMBER traffic Light**
- Salofalk granules 500mg, 1000mg, 1500mg, and 3000mg PR granules:** requested by Dr J Collum (Consultant Physician & Gastroenterologist Clinical Director: ELHT Digestive Diseases) for maintenance of remission of Ulcerative Colitis in patients who are intolerant or uncontrolled on other 5ASA formulations. Approved for use. **AMBER traffic Light**

**Resolved:** Formulary will be updated accordingly.

#### **2023/73: Formulary Updates**

- Tirosint 25mcg** (levothyroxine capsules): requested for specific patient who reports being intolerant to all brands of tablet. Capsules cost approximately £87 per pack. **Resolved:** Not supported by group members.



- b. **Metolazone tablets:** currently Red traffic light on ELMMB, with request to change to AMBER for oedema, hypertension in line with LSCMMG. ELMMB originally agreed a red traffic light due to the drug being an unlicensed product. A licensed product is now available but there has since been a shortage and more recently a drug safety alert as the unlicensed product is not bioequivalent to the licensed product (Xaqua®). The safety concerns recommend that metolazone must be prescribed by brand. However, this comes with a cost implication for primary care should the unlicensed product (Zaroxolyn 2.5mg and 5mg tablets) is prescribed. LR will take this back as an action to LSCMMG requesting the licensed product is the only brand used. To remain as RED Traffic Light  
**RED Traffic Light**
- c. **Terizidone 250mg capsules:** this is a commissioned drug for tuberculosis for use when formulary cycloserine is not available.  
**RED Traffic Light**
- d. **CareSens S Fit BT:** cost effective blood glucose testing strip replacing Tee2+ test strips on formulary.  
**GREEN Traffic Light**
- e. **Civasta (melatonin) 2mg MR tablets:** cost effective option to be used in place of Circadin for poor sleep in paediatric. Approved and decision to feed back to LSCMMG for adoption across LSC.  
**AMBER Traffic Light**
- f. **Zuclopenthixol decanoate injection:** for information approved by Pharmacy and Medicines Policy Task and Finish Group for the maintenance treatment of schizophrenia and paranoid psychosis.  
**AMBER Traffic Light**
- g. **Brancico XL (quetiapine):** request to use as a cost-effective brand.
- h. **Oxyact® (oxycodone tablets):** request to use as a cost-effective brand.
- i. **Oxylan (oxycodone MR):** request to use as a cost-effective brand.
- j. **Rebrikel 5mcg/hour** (buprenorphine patches); request to use as a cost-effective brand.
- k. **Rebrikel 10mcg/hour:** request to use as a cost-effective brand.
- l. **Rebrikel 20mcg/hour:** request to use as a cost-effective brand.  
Items g – i approved for use, safety messages to be added to Optimise Rx and Hot Topic to inform practices of the changes  
**AMBER Traffic Light**

**Resolved:** ELMMB formulary will be updated accordingly

#### 2023/74 LSCMMG Consultations – May 2023 [deadline 6<sup>th</sup> July 2023]

- a. **Fluorouracil 5% Cream for treatment of superficial pre-malignant skin lesions**  
Recommendation - GREEN for the following indications: Topical treatment of superficial pre-malignant skin lesions. Supported by dermatology. SJ commented that that the reference to Bowen's and actinic keratosis disease should not be included in the recommendation and that the leaflet be shared with GP's.
- b. **Melatonin prescribing guidance (pathway) children:** Comments included the difficulty of having no sleep clinic. It was suggested that a 1-page guidance sheet on medication may be more preferable.
- c. **Softacort NMR additional information (addendum),** additional information provided by requesting ophthalmologist. For treatment of mild non-infectious allergic or



inflammatory conjunctival diseases NMR – RED RAG Recommendation. Feedback from ELHT Ophthalmologists last consultation to be resubmitted (amber) for this consultation.

All documents have been circulated to appropriate directorate.

**For Action:** Comments to be sent to LSCMMG.

#### **2023/75 LSCMMG Recommendations –April 2023**

- a. Trans anal irrigation devices – updated guidance.
- b. Vitamin D position statement – updated guidance.
- c. Colomycin® prescriber information sheet – updated guidance.
- d. Asthma guideline - minor update

**Resolved:** items acknowledged by ELMMB. Website will be updated accordingly.

#### **2023/76 LSCMMG Recommendations – May 2023**

- a. MHRA Alert: JAK inhibitors - Link added to each JAK inhibitor medicine page
- b. Sodium Zirconium Cyclosilicate – Evidence Review – no RAG change
- c. Camouflaging Products – Updated
- d. Sevelamer generic

**Resolved:** items acknowledged by ELMMB. Website will be updated accordingly.

#### **2023/77 Other Items**

**Self-Injection of Vitamin B12 in Crohn's disease:** Request from Dr Grimley, gastroenterology, for initially one patient only who struggles to attend her GP practice due to work pressures. There are other surgeries around the country that support self-administration and resources to support self-administration are in draft and were circulated to the group. The traffic light will remain the same.

**Resolved:** Approved. Leaflet will be finalised for self-administration for this patient at the one practice.

#### **2023/78 Other Items**

**ELHT Wound Care Formulary document (v1.4):** ELHT has a new formulary and new delivery model. Under new arrangements the products will be ordered centrally via NHS supplies and hence GPs will no longer be asked to prescribe for wound care products. However, GPs will still be required to issue an FP10 for requests from Nursing Homes (this does not include non-nursing care homes/residential homes). District nurses will order products directly from NHS supplies for delivery to specific hubs across the locality: streamlining the ordering and supply function, speed up response times and reduce waste. Products should not be left within homes unlabelled.

**Resolved:** Item acknowledged by ELMMB

#### **2023/79 Other Items**

**Inclisiran:** LR presented documents for adoption by ELMMB. They support administration, payments, availability, costs and wholesalers.



**Resolved:** ELMMB logo to be added to documents, uploaded to website and share with LSCMMG for adoption across LSC.

#### 2023/80 Other Items

The recent **MHRA Drug Safety Update** regarding direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment.

**Resolved:** It was agreed to add the resources within the bulletin to the website.

#### 2023/81 Other Items

**Ivermectin:** The unlicensed use of Ivermectin for scabies, on the advice of dermatology, has seen an increase recently. Community pharmacies find it hard to obtain and most supplies can take 5 days or more. There is also a hesitancy amongst GPs to prescribe. JV asked if there was a need or possibility for the IMOT to keep stock? HR suggested that perhaps some community pharmacies can keep some stock as well as hospital?

**Action:** HR agreed to look into this with the IMOT team and will feed back to next meeting.

#### 2023/82 Other Items

##### **L&SC formulary - East CV omissions:**

LSCMMG have identified some omissions within the ELMMB CV section. These are Felodipine, Bezafibrate, Nebivolol and Tranexamic acid injection. To feed back to LSCMMG that group would agree with AMBER for Felodipine, Nebivolol and Bezafibrate [not in NICE guidance for Primary Care use] and Red for Tranexamic acid injection.

##### **L&SC formulary - East Lancs CV Anomalies:**

Metolazone to remain red – see item 2023/73 b.  
Ivabradine change to amber  
Ranolazine to change to amber  
Pindolol - remove from formulary  
Danaparoid sodium - add as RED  
Labetalol (oral) – to remain as amber,  
Furosemide 500mg tablets – to remain as amber

**Action:** JV to feed back to LSCMMG

#### 2023/83 NICE Guidance –April and May 2023

**CG181** Cardiovascular disease: risk assessment and reduction, including lipid modification. **Updated** 24<sup>th</sup> May 2023

**NG198** Acne vulgaris: management. **Updated** 17<sup>th</sup> May 2023

**NG18** Diabetes (type 1 and type 2) in children and young people: diagnosis and management. **Updated** 11<sup>th</sup> May 2023

**NG133** Hypertension in pregnancy: diagnosis and management. **Updated** 17<sup>th</sup> April 2023

**NG101** Early and locally advanced breast cancer: diagnosis and management. **Updated** 5<sup>th</sup> April 2023



**2023/84 NICE Recommendations – April and May 2023**

Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 is recommended as an option by **NICE TA878**  
**ICB Commissioned, Blueteq required** **Traffic Light RED**

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment not recommended by **NICE TA879**  
Terminated appraisal **Traffic Light BLACK**

Tezepelumab for treating severe asthma is recommended as an option in **NICE TA880**  
**NHS England Commissioned** **Traffic Light RED**

Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments is not recommended as in **NICE TA881**  
**NHS England Commissioned** **Traffic Light BLACK**

Voclosporin with mycophenolate mofetil for treating lupus nephritis is recommended as an option in **NICE TA882**  
**NHS England Commissioned** **Traffic Light RED**

Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma is not recommended as an option in **NICE TA883**  
**NHS England Commissioned** **Traffic Light BLACK**

Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping. Terminated appraisal as by **NICE TA884**. **Traffic Light BLACK**

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer is recommended as an option in **NICE TA885**.  
**Cancer Drug Fund** **Traffic Light RED**

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy is recommended as an option in **NICE TA886**  
**NHS England Commissioned** **Traffic Light RED**

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer is recommended as an option in **NICE TA887**.  
**NHS England Commissioned** **Traffic Light RED**

Risankizumab for previously treated moderately to severely active Crohn's disease is recommended as an option in **NICE TA888**.  
**ICB Commissioned, Blueteq required** **Traffic Light RED**

Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma. Terminated appraisal as by **NICE TA889** **Traffic Light BLACK**

Difelikefalin for treating pruritus in people having haemodialysis is recommended as an option in **NICE TA890**.  
**NHS England Commissioned** **Traffic Light RED**





Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia is recommended as an option in **NICE TA891**

**NHS England Commissioned**

**Traffic Light RED**

Mosunetuzumab for treating relapsed or refractory follicular lymphoma is not recommended as an option in **NICE TA892**

**NHS England Commissioned**

**Traffic Light BLACK**

**2023/85 NICE Highly Specialised Technologies – April- May 2023**

**HST15 Onasemnogene abeparvovec** for treating spinal muscular atrophy. **Updated** 19<sup>th</sup> April 2023

**HST24 Onasemnogene abeparvovec** for treating presymptomatic spinal muscular atrophy. **Published** 19<sup>th</sup> April 2023.

**HST25 Lumasiran** for treating primary hyperoxaluria type 1. **Published** 19<sup>th</sup> April 2023.

**HST26 Eladocogene exuparvovec** for treating aromatic L-amino acid decarboxylase deficiency. **Published** 19<sup>th</sup> April 2023.

**2023/86 EAMS (Early access to medicines scheme) – April and May 2023**

None

**Standing Items:**

**2023/87 For Action/Information:** Lancashire & South Cumbria Medicines Management Group (LSCMMG)

- a. LSCMMG-minutes-final 20.04.2023
- b. LSCMMG-minutes-draft 10.05.2023

**Resolved:** acknowledged

**2023/88 For Action/Information:** Lancashire & South Cumbria FT Drugs and Therapeutics Committee

Minutes and open action tracker from 25<sup>th</sup> May 2023 acknowledged.

**2023/89 For Action/Information:** Antimicrobial Stewardship Committee (ASC)

14<sup>th</sup> March 2023 minutes not available yet. (April and May Meetings cancelled)

**DATE OF NEXT MEETING – Wednesday 19<sup>th</sup> July 2023 12.30pm via ‘Microsoft Teams’**



**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY 22nd February 2023**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2021/101b</b>	<b>ELMMB Membership</b>  A review will be required to decide how ELMMB links with the ICS and ICB in the future and the policy for introduction of new drugs will require review as a result of that. New stakeholders to be considered. Await full ICB structure.  ELMMB Terms of reference to be reviewed to reflect future meetings.	LR/VG/AB/HR	July 23
<b>2023/26</b>	<b>GLT2i dosing considerations according to eGFR when treating T2D, HF or CKD – Draft version.</b>  updated/final document to be brought back to next meeting	AF	July 23
<b>2023/81</b>	<b>Ivermectin</b>  HR agreed to look into this with the IMOT team and will feed back to next meeting.	HR	July 23
<b>2023/82</b>	<b>L&amp;SC formulary - East CV omissions and L&amp;SC formulary - East Lancs CV Anomalies</b>  JV to feed back to LSCMMG	JV	July 23